Highly Effective New Anti-Cancer Drug Showing Few Side Effects in Mice
A recent study was done by the University of Chicago Medical Center to create a drug that could fight aggressive lung cancers. Professor Yuck Mazurka, the author of the experiment, screened around 30,000 compounds and found a few that were most likely to work in humans. What was known about these aggressive cancers was the protein TOP. This protein is produced in many human cancers and is thought to encourage the growth of tumors.
Professor Yuck Mazurka wanted to target this protein with the new drug that lowered levels of toxicity while still shrinking tumors- this drug ended up being named TOASTS. In order to test the drug, six mice with LU-99 lung tumors were injected with the drug and studied over a period of two weeks. All the mice recovered from the tumors. In five of the six tested mice the tumors completely shrunk all under 30 days. Even after the drug was no longer administered, all six mice still showed signs of tumor shrinkage.
However, their red blood cell count was very low, but they all recovered from this deficiency within two weeks. When tested, no toxicity was detected from the drug. In an earlier drug though, homeopathic toxicity was found- which Increases risk of Infections and can cause anemia. They wanted to avoid this. The experiment was highly successful and should be considered a major breakthrough In cancer drugs. The research Is not only important for aggressive lung cancers, but can be applied to other cancers as well. Very few drugs have been able to shrink cancerous tumors so quickly.
To add to how fantastic this experiment was, Mazurka actually stepped down from his position of the “Director In the Japanese Government’s Office of Medical Innovation to Join the Medical Center” and their research on these cancer drugs. Now, they want to begin a clinical trial as soon as Fall of 201 5, hopefully to benefit cancer patients and cancer research as a whole. Mazurka and his team mentioned using TOASTS on other forms of cancers. Should the drug be tested on mice with different types of tumors or does the one study of the LU-ass’s suffice?
In regards to this question, I hope to find another article published on the results off clinical trial and Its success In humans. This drug Is another step In not only cancer research, but genetics as well. Works Cited http:/Damn. Eclectically. Com/releases/2014/10/141022143559. HTML drug that could fight aggressive lung cancers. Professor Yuck Mazurka, the six mice with LIZ-99 lung tumors were injected with the drug and studied over a Hough, homeopathic toxicity was found- which increases risk of infections and can should be considered a major breakthrough in cancer drugs.
The research is not only the “Director in the Japanese Government’s Office of Medical Innovation to Join the study of the LIZ-ass’s suffice? In regards to this question, I hope to find another article published on the results of a clinical trial and its success in humans. This drug is another step in not only cancer research, but genetics as well.